The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.
Open accessAbstract
The use of growth hormone (GH) as an anabolic agent is limited by its tendency to cause hyperglycemia and by its inability to reverse nitrogen wasting in some catabolic conditions. In a previous study comparing the anabolic actions of GH and IGF-I (insulin-like growth factor I), we observed that intravenous infusions of IGF-I (12 micrograms/kg ideal body wt [IBW]/h) attenuated nitrogen wasting to a degree comparable to GH given subcutaneously at a standard dose of 0.05 mg/kg IBW per d. IGF-I, however, had a tendency to cause hypoglycemia. In the present study, we treated seven calorically restricted (20 kcal/kg IBW per d) normal volunteers with a combination of GH and IGF-I (using the same doses as in the previous study) and compared its effects on anabolism and carbohydrate metabolism to treatment with IGF-I alone. The GH/IGF-I combination caused significantly greater nitrogen retention (262 +/- 43 mmol/d, mean +/- SD) compared to IGF-I alone (108 +/- 29 mmol/d; P < 0.001). GH/IGF-I treatment resulted in substantial urinary potassium conservation (34 +/- 3 mmol/d, mean +/- SE; P < 0.001), suggesting that most protein accretion occurred in muscle and connective tissue. GH attenuated the hypoglycemia induced by IGF-I as indicated by fewer hypoglycemic episodes and higher capillary blood glucose concentrations on GH/IGF-I (4.3 +/- 1.0 mmol/liter, mean +/- SD) compared to IGF-I alone (3.8 +/- 0.8 mmol/liter; P < 0.001). IGF-I caused a marked decline in C-peptide (1,165 +/- 341 pmol/liter; mean +/- SD) compared to the GH/IGF-I combination (2,280 +/- 612 pmol/liter; P < 0.001), suggesting maintenance of normal carbohydrate metabolism with the latter regimen. GH/IGF-I produced higher serum IGF-I concentrations (1,854 +/- 708 micrograms/liter; mean +/- SD) compared to IGF-I only treatment (1,092 +/- 503 micrograms/liter; P < 0.001). This observation was associated with increased concentrations of IGF binding protein 3 and acid-labile subunit on GH/IGF-I treatment and decreased concentrations on IGF-I alone. These results suggest that the combination of GH and IGF-I treatment is substantially more anabolic than either IGF-I or GH alone. GH/IGF-I treatment also attenuates the hypoglycemia caused by IGF-I alone. GH/IGF-I treatment could have important applications in diseases associated with catabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Short-Term Metabolic Effects of Recombinant Human Insulin-like Growth Factor I in Healthy Adults
Guler, H.-P., Zapf, J., & Froesch, E. R. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170303 · Cited by 554
Insulin-like growth factors I and II in healthy man.
Guler, H.-P., Zapf, J., Schmid, C., & Froesch, E. R. (1989) · Acta Endocrinologica · doi:10.1530/acta.0.1210753 · Cited by 531
STREAT, S. J., BEDDOE, A. H., & HILL, G. L. (1987) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-198703000-00006 · Cited by 474
Guler, H. P., Zapf, J., Scheiwiller, E., & Froesch, E. R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4889 · Cited by 422
Human growth hormone prevents the protein catabolic side effects of prednisone in humans.
Horber, F. F., & Haymond, M. W. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114694 · Cited by 407
Fukagawa, N. K., Minaker, K. L., Rowe, J. W., Goodman, M. N., Matthews, D. E., Bier, D. M., & Young, V. R. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112240 · Cited by 367
Compartmental body composition based on total-body nitrogen, potassium, and calcium
Cohn, S. H., Vartsky, D., Yasumura, S., Sawitsky, A., Zanzi, I., Vaswani, A., & Ellis, K. J. (1980) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1980.239.6.e524 · Cited by 342
Guler, H. P., Schmid, C., Zapf, J., & Froesch, E. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2868 · Cited by 322
Baxter, R. C., & Martin, J. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.6898 · Cited by 307
Self-citationJacob, R., Barrett, E., Plewe, G., Fagin, K. D., & Sherwin, R. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114072 · Cited by 290
Cited by
Nutritional Regulation of the Insulin-Like Growth Factors*
THISSEN, J.-P., KETELSLEGERS, J.-M., & UNDERWOOD, L. E. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-1-80 · Cited by 1,579
Self-citationOhlsson, C., Bengtsson, B.-A., Isaksson, O. G. P., Andreassen, T. T., & Slootweg, M. C. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0324 · Cited by 855
Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations
Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487
Regulation of muscle mass by growth hormone and IGF‐I
Velloso, C. P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.153 · Cited by 442
Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders
Playford, R. J., Macdonald, C. E., & Johnson, W. S. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.1.5 · Cited by 389
Metadata
- Authors
- Kupfer, S. R., Underwood, L. E., Baxter, R. C., & Clemmons, D. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1993-02-01
- Volume
- 91
- Issue
- 2
- Pages
- 391-396
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2134758256
- Cited by
- 337
- References
- 36
- FWCI
- 31.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. https://app.cochat.ai/papers/10.1172/jci116212
- The paper
- Kupfer, S. R., Underwood, L. E., Baxter, R. C., & Clemmons, D. R. (1993). Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. Journal of Clinical Investigation. https://doi.org/10.1172/jci116212
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.